May 9, 2022. We agree with USPSTF’s “I” grade recommendation regarding anxiety screening for children 7 years or younger, since there is not sufficient evidence on the benefits and harms of screening for this age group, or to determine the impact of treatments for anxiety in children in this age group. However, regarding screening for anxiety in asymptomatic children between the ages of 8 and 18, we do not agree with USPSTF’s “B” grade recommendation, because of the lack of direct evidence to support USPSTF’s recommendation.
Read More »On Health Policy
Nonprofit Consumer and Public Health Organization’s Letter To FDA Regarding Transparency Of The MDUFA V Reauthorization Process
March 4, 2022: We write today to follow up on your response to several requests for information at the Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) Medical Device User Fee Amendments (MDUFA V) stakeholders meeting on February 28, 2022.
Read More »NCHR Comments on Screening for Obstructive Sleep Apnea in Adults
April 25, 2022. Despite the recent increase in obstructive sleep apnea (OSA), we agree with the “I” grade recommendation for OSA screening in asymptomatic adults or those with unrecognized symptoms, as there is currently insufficient evidence to assess the benefits and harms of screening.
Read More »NCHR Comments on the MDUFA V Commitment Letter
April 21, 2022: NCHR would like to express our substantial concerns with the overall process as well as the shortcomings of the Commitment letter.
Read More »NCHR Comments on the Proposed 2022 Center for Disease Control (CDC) Clinical Practice Guideline for Prescribing Opioids
April 11, 2022: We commend the CDC for their continued efforts to reduce opioid use. However, we are very concerned that the impact of the Box 1 Guideline as currently written will be very harmful to patients.
Read More »